Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a nucleosidic inhibitor-resistant retrovirus or a non-nucleosidic inhibitor-resistantretrovirus
CA 2424869 A1 · Owner: Wagner, Ralf · Inventors: Notka, Frank; Wagner, Ralf
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use a Phyllanthus extract or a fraction thereof or a gallotannin or a combination of gallontannins for the preparation of a pharmaceutical composition for the prevention or treatment of retrovirus related diseases associated with a nucleosidic inhibitor-resistant retrovirus and/or a non-nucleosidic inhibitor-resistant retrovirus. Preferably the , retrovirus is a human immunodeficiency virus (HIV). In accordance with the present invention, it is further preferred that said gallotannin or combination of gallotannins is or comprises corilagin and/or geraniin and another ellagitannin. Further preferred is that said Phyllanthus is Phyllanthus amarus.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 5, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 5, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 5, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.